Navigation Links
Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals
Date:7/23/2014

Cambridge, MA (PRWEB) July 23, 2014

Astra Nova Training, a global provider of innovative and comprehensive consultancy and pharma training services, and the Alliance for Clinical Research Excellence and Safety (ACRES), a non-profit integrating the expertise and investments of research stakeholders worldwide to build and maintain a global system for clinical trials, are pleased to announce a strategic alliance collaboration to improve the expertise of industry professionals through improved and easily available training quality, thus enhancing greater patient safety.

Since its establishment in 2008, UK-based Astra Nova has introduced an international network of over 140 industry experts based in over 50 countries around the globe. In addition, the company has launched over 20 free and commercial online training courses, accessible on their Learning Management System. More than 5,000 professionals worldwide have obtained industry certification through their in-house and online training solutions.

ACRES, a non-profit organization operating in the public interest, is dedicated to enhancing quality, safety, integrity, and operational effectiveness in drug development and health research through the building of a global system for clinical research. To achieve this, ACRES has adopted an Alliance-based model whereby those organizations with a stake in clinical trials being conducted according to the highest standards of safety, quality, and efficiency, are the very organizations that—together—build the comprehensive, integrated system to make such excellence possible.

Astra Nova, with its strong commitment to corporate social responsibility (CSR), will make available interactive and easy-to access online training solutions for ACRES Global Platform of services. This CSR commitment, mirrored by ACRES, is exemplified in Astra Nova’s Better Industry Initiative (Bii), which provides free and commercial high-quality training courses and other resources, with an ultimate goal of better serving patients by equipping future and current industry professionals with more refined skills and workflow efficiency tools.

With Astra Nova, ACRES will provide timely information on critical training topics and materials needed globally, and they will partner on Learning Management Systems development. Other collaborative efforts involve jointly organizing multi-stakeholder events dedicated to improving the conduct of clinical research globally.

Astra Nova’s Business Development Director, Ms. Maya Zlatanova, said: “Our main goal is to improve patient safety and allow easier access to industry regulations, standards, and knowledge. We believe that everyone will benefit from this partnership, and the results of this collaboration will become visible in the very first days of establishing it.”

Dr Matthew Whalen, COO of ACRES, noted, “ACRES work is conducted through alliances, and Astra Nova brings added depth to ACRES network of organizations committed to transforming the world of clinical research.” Whalen added, “We are looking forward to working together with Astra Nova in a variety of ways to realize our shared collaboration goal of providing more innovative solutions, broader standardization, better quality of service, greater safety, and increased efficiency.”

ASTRA NOVA LTD:

More information on Astra Nova’s work can be found here. For more information, please contact Ms. Maya Zlatanova at maya(at)astranovatraining(dot)co(dot)uk.

ACRES:

More information on the Alliance for Clinical Research Excellence and Safety (ACRES) may be found here. For more information, please contact Dr. Mary F. Tobin at mtobin(at)acresglobal(dot)net.

Read the full story at http://www.prweb.com/releases/ACRES_AstraNova_Research/GregKoskiMayaZlatanove/prweb12035287.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Announces Collaboration With AstraZeneca on the Analysis of Compound Combination Experiments
2. New Drug Applications, FDA Approvals, Approved Acquisitions, Divestitures and Licensing Agreements - Research Report on Merck, Allergan, Mylan, AstraZeneca, and GlaxoSmithKline
3. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
4. Todays Technical View: AstraZeneca, GlaxoSmithKline, Keryx Biopharma, and Raptor Pharma
5. Top Five Global Cardiovascular Drug Companies 2013 Report Features Players such as Pfizer and AstraZeneca
6. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
7. Isis Pharmaceuticals Earns $10 Million Milestone Payment from AstraZeneca for ISIS-AR Rx to Treat Prostate Cancer
8. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
9. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
10. UroToday Launches New Prostate Cancer Focused Content Including Immunotherapy for Metastatic Castration-resistant Patients
11. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):